Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

34.45 -0.60 (-1.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
3 Magnificent Stocks Under $100 to Buy in November
The price could be right for these stocks. 
Via The Motley Fool
Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
The top 10 performers last week were Reddit, Paycom, Mobileye, Exelixis, Garmin, Roblox, Twilio, Snap, Waters, and Atlassian. Many analysts raised price forecasts. 
Via Benzinga
Earnings Preview: Exelixis
Via Benzinga
1 No-Brainer Stock to Buy With $40
The midcap biotech just became an even better buy. 
Via The Motley Fool
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Biotech Momentum Trades For The Q4 Rally
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
Analyst Ratings For Exelixis
Via Benzinga
Navigating 16 Analyst Ratings For Exelixis
Via Benzinga
Key Takeaways From Exelixis Analyst Ratings
Via Benzinga
A Closer Look at 5 Analyst Recommendations For Exelixis
Via Benzinga
Momentum Has Narrowed Again, Significantly
It is more of a stock pickers market than usual as momentum factors are currently exaggerated. 
Via Talk Markets
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
NASDAQ:EXEL, an undervalued stock with good fundamentals.
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
It is Fall clean up time. Sell lagging and sagging companies. 
Via Talk Markets
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
Via Chartmill
2 Growth Stocks to Buy With Less Than $100
No need to break the bank to get in on these likely long-term winners. 
Via The Motley Fool
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
From Exelixis, Inc.
Via Business Wire
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
From Exelixis, Inc.
Via Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.